Analyst Research
| Report Title | Price |
|---|---|
|
Provider: Reuters Investment Profile
|
$20.00
|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
|
Provider: Jefferson Research
|
$20.00
|
|
Provider: ValuEngine, Inc.
|
$127.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Vascular Solutions Inc Issues Q1, FY 2013 Guidance In Line With Analysts' Estimates
Vascular Solutions Inc announced that for fiscal 2013, it expects net revenue to between $106-$110 million, net earnings to between $0.66-$0.70 per fully diluted share. For the first quarter of 2013, it expects net revenue of between $26.0-$27.0 million and net earnings to be between $0.15-$0.16 per diluted share. According to I/B/E/S Estimates, analysts are expecting the Company to report revenue of $109 million and EPS of $0.68 for fiscal 2013; revenue of $26.7 million and EPS of $0.16 for first quarter of 2013.
Latest Developments for Vascular Solutions Inc
- Vascular Solutions Inc Reaffirms FY 2013 Guidance; Issues Q2 2013 In Line With Analysts' Estimates
- Vascular Solutions Inc Raises FY 2012 Revenue Guidance; Raises Low End Of Prior FY 2012 EPS Guidance; Issues Q4 2012 Guidance In Line With Analysts' Estimates
- Vascular Solutions, Inc. Raises FY 2012 Guidance; Issues Q3 2012 Guidance; Revenue Guidance Above Analysts' Estimates
- Vascular Solutions, Inc. Issues Q2 2012 Guidance; Revenue Guidance Above Analysts' Estimates; Raises FY 2012 Guidance
Latest Key Developments in Advanced
- Covidien PLC Approves Separation Of Pharmaceuticals Business And Declares Dividend Of Mallinckrodt Ordinary Shares
- Nephros Inc Announces Completion Of Rights Offering
- Volcano Corp Announces Preliminary Results From ADVISE II Study
- Nordion Inc Enters Into Agreement To Divest Targeted Therapies Business To BTG Plc
- Share this
- Link this
- Digg this
Follow Reuters